Total Price: $0.00
Contact Information
Recombinant Human PCSK9 Protein (His tag)
SKU: PDMH100129-100
To better serve you, we would like to discuss your specific requirement.
Please Contact Us for a quote.
Recombinant Human PCSK9 Protein (His tag)
| SKU # | PDMH100129 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | NARC-1, NARC1, Neural Apoptosis-Regulated Convertase 1, PC9, PCSK9, Proprotein Convertase 9, Proprotein Convertase Subtilisin/Kexin Type 9, Subtilisin/Kexin-Like Protease PC9 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met1-Gln692 |
| Accession | Q8NBP7 |
| Calculated Molecular Weight | 76.0 kDa |
| Observed Molecular Weight | 60 kDa |
| Tag | C-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95% as determined by reducing SDS-PAGE. |
| Endotoxin | Please contact us for more information. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
Background
Human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER , the pro domain and mature chain secrete together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.